KRAS G12C — Drug Target

All drugs that target KRAS G12C — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

KRAS G12C inhibitor

Phase 3 pipeline (3)

• MRTX849 · Mirati Therapeutics Inc. · KRAS G12C inhibitor · Oncology
  MRTX849 is a small-molecule inhibitor that selectively targets KRAS G12C mutations, blocking oncogenic signaling in cancer cells.
• AMG 510 · Criterium, Inc. · KRAS G12C inhibitor · Oncology
  AMG 510 is a small-molecule inhibitor that selectively targets KRAS G12C mutations, blocking oncogenic signaling in cancer cells.
• RMC-6236 · Revolution Medicines, Inc. · KRAS G12C inhibitor · Oncology
  RMC-6236 is a selective inhibitor of KRAS G12C mutations that blocks oncogenic signaling in cancer cells.

Phase 2 pipeline (1)

• DCL-101 vs Golytely · Dark Canyon Laboratories, LLC · KRAS G12C inhibitor · Oncology
  DCL-101 is a small molecule that targets the KRAS G12C mutation, inhibiting the KRAS protein's ability to promote cancer cell growth.